1例直肠癌患者新辅助化疗发生肺栓塞的药学干预实践

doi:10.19803/j.1672-8629.2021.01.16

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (1): 80-83.
DOI: 10.19803/j.1672-8629.2021.01.16

1例直肠癌患者新辅助化疗发生肺栓塞的药学干预实践

曲国红^1,2, 陈喆^1,*

¹国家癌症中心/国家肿瘤临床医学研究中心,中国医学科学院北京协和医学院肿瘤医院药剂科,北京 100021;
²南京医科大学附属老年医院,江苏省省级机关医院药学部,江苏南京 210024

收稿日期:2019-11-03 修回日期:2021-01-18 出版日期:2021-01-15 发布日期:2021-01-18
通讯作者: ^*陈喆,女,硕士,主管药师,临床药学。E-mail:gigichen79@126.com
作者简介:曲国红,女,硕士,主管药师,临床药学。
基金资助:
江苏省药学会(A201710); 南京市药学会(2017YX016)

Pharmaceutical Intervention for Pulmonary Embolism in a Rectal Cancer Patient Treated with New Assisted Chemotherapy

QU Guohong^1,2, CHEN Zhe^1,*

¹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;
²Geriatric Hospital of Nanjing Medical University/Jiangsu Provincial Government Hospital,Department of Pharmacy,Nanjing Jiangsu 210024,China

Received:2019-11-03 Revised:2021-01-18 Online:2021-01-15 Published:2021-01-18

摘要/Abstract

摘要： 目的介绍贝伐珠单抗致肺栓塞的药学实践。方法临床药师通过查阅文献及相关指南,对1例贝伐珠单抗联合化疗致肺栓塞不良反应进行评估,结合患者病情及意愿对抗凝药物选择提供建议及监护。结果临床药师提出药品不良反应处理方案,医师采纳建议,患者肺栓塞控制良好。结论临床药师与医师合作,以患者为中心,保障患者用药安全,为临床合理用药提供参考。

关键词: 临床药师, 肺栓塞, 药品不良反应

Abstract: Objective To introduce the pharmaceutical disposal one case of pulmonary embolism induced by bevacizumab.Methods Two clinical pharmacists participated in the evaluation of adverse reactions of pulmonary embolism induced by bevacizumab in combination with chemotherapy by consulting related literature and guidelines.Based on the patient's condition and willingness,the pharmacist gave advice on the selection of anticoagulants.Results The clinical pharmacists recommended solutions to the ADR,the physician adopted the recommendation,the patient's pulmonary embolish was well controlled.Conclusion Clinical pharmacists are expected to cooperate with clinicians,give a top priority to the safety of patients and give advice on clinical rational drug use.

Key words: clinical pharmacist, pulmonary embolism, adverse drug reaction

中图分类号:

R969.3

曲国红, 陈喆. 1例直肠癌患者新辅助化疗发生肺栓塞的药学干预实践[J]. 中国药物警戒, 2021, 18(1): 80-83.

QU Guohong, CHEN Zhe. Pharmaceutical Intervention for Pulmonary Embolism in a Rectal Cancer Patient Treated with New Assisted Chemotherapy[J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 80-83.

参考文献

[1] Ferrara N,Hillan KJ,Gerber HP.Discovery and development of bevacizumab,an anti-VEGF antibody for treating cancer[J].Nat Rev Drug Discov,2004,3(5):391-400.
[2] Keating GM .Bevacizumab:a review of its use in advanced cancer[J].Drugs,2014,74(16):1891-1925.
[3] Escudier B,Pluzanska A,Koralewski P,et al.Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma:a randomised,double-blind phase III trial[J].Lancet,2007,370(9605):2103-2111.
[4] Yan CR,Zhang MY,Ma WB.Recent advance in bevacizumab for high-grade gliomas[J].Chinese Journal of Neurosurgery(中华神经外科杂志),2016,32(1):88-90.
[5] Xu BH,Jiang ZF,Shen ZZ,et al.Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer:findings from the ATHENA study[J].Chin Med J(Engl),2012,125(5):764-769.
[6] Burger RA,Brady MF,Bookman MA,et al.Incorporation of bevacizumab in the primary treatment of ovarian cancer[J].N Engl J Med,2011,365(26):2473-2483.
[7] Niho S,Kunitoh H,Nokihara H.Randomized phase II study of first-line carboplatin- paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer[J].Lung Cancer,2012,76:362-367.
[8] Khorana AA,Francis CW,Culakova E,et al .Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy[J].Journal of Thrombosis and Haemostasis,2007,5(3):632-634.
[9] Zhao R,Zhao BQ,Zhang YH.Adverse reactions of bevacizumab in the treatment of malignant tumor[J].Chinese Journal of New Drugs(中国新药杂志),2003,22(17):2097-2102.
[10] Pu J,Chan R,Ng G,et al.Using bevacizumab in the fight against malignant glioma:First results in Asian patients[J].Hong Kong Med J,2011,17(4):274-279.
[11] Nalluri SR,Chu D,Keresztes R,et al.Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients:meta-analysis[J].JAMA,2008,300(19):2277.
[12] Kilickap S,Abali H,Celik I.Bevacizumab,bleeding,thrombosis,and warfarin[J].Journal of Clinical Oncology:Official Journal of the American Society of Clinical Oncology,2003,21(18):3542-3543.
[13] Zachary I.Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor[J].American Journal of Physiology-Cell Physiology,2001,280(6):1375-1386.
[14] Tam BYY,Wei K,Rudge JS,et al.VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis[J].Nature Medicine,2006,12(7):793-800.
[15] Hesser BA.Down syndrome critical region protein 1 (DSCR1),a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells[J].Blood,2004,104(1):149-158.
[16] Cui XL,Wan ZR,Hou KL,et al.Overview of Dugs Increasing the Risk of VTE or Thrombosis in Patients with Cancer[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2017,14(7):430-434.
[17] Chikako M,Yugo C,Satoko S,et al.Evaluation of thromboembolic events in cancer patients receiving bevacizumab according to the Japanese Adverse Drug Event Report database[J].Journal of oncology pharmacy practice,2016,24(1):22-27.
[18] Chinese Thoracic Society Pulmonary Embolism and Pulmonary Vascular Disease Group.practice guidelines in pulmonary throm-boembolism:Prevention,Screening,and Treatment[J].National Medical Journal of China(中华医学杂志),2018,98(14):1060-1087.
[19] Khorana AA,Noble S,Lee AYY,et al.Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism:guidance from the SSC of the ISTH[J].Journal of Thrombosis and Haemostasis,2018,16(9):1891-1894.
[20] The EINSTEIN-PE Investigators.Oral rivaroxaban for the treatment of symptomatic pulmonary embolism[J].New England Journal of Medicine,2012,366(14):1287-1297.
[21] Young AM,Marshall A,Thirlwall J,et al.Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism:results of a randomized trial (SELECT-D)[J].Journal of Clinical Oncology,2018,36(20):2017-2023.

1例直肠癌患者新辅助化疗发生肺栓塞的药学干预实践

Pharmaceutical Intervention for Pulmonary Embolism in a Rectal Cancer Patient Treated with New Assisted Chemotherapy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[3]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[4]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[5]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[6]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[7]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[8]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[9]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[10]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[11]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[12]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[13]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[14]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[15]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.